- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/00 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
Patent holdings for IPC class C07D 217/00
Total number of patents in this class: 132
10-year publication summary
|
6
|
3
|
7
|
7
|
8
|
4
|
7
|
2
|
3
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4751 |
7 |
| Merck Sharp & Dohme LLC | 3736 |
5 |
| Boehringer Ingelheim International GmbH | 4493 |
4 |
| Alcon, Inc. | 5876 |
3 |
| Epizyme, Inc. | 360 |
3 |
| OPKO Health, Inc. | 44 |
3 |
| Shanghai Lumosa Therapeutics Co., Ltd. | 14 |
3 |
| Shanghai Yingli Pharmaceutical Co., Ltd. | 49 |
3 |
| SpecGx LLC | 186 |
3 |
| Hoffmann-La Roche Inc. | 3796 |
2 |
| Merck Sharp & Dohme Corp. | 2183 |
2 |
| Takeda Pharmaceutical Company Limited | 2710 |
2 |
| Aerie Pharmaceuticals, Inc. | 38 |
2 |
| Ardelyx, Inc. | 119 |
2 |
| Cyrenaic Pharmaceuticals Inc. | 2 |
2 |
| University of Kentucky Research Foundation | 716 |
2 |
| Epiodyne, Inc. | 7 |
2 |
| Bausch + Lomb Ireland Limited | 728 |
2 |
| Innovstone Therapeutics Limited | 33 |
2 |
| Novartis AG | 10251 |
1 |
| Other owners | 77 |